Packaging Defect Found in Pfizer Vaccine in Hong Kong and Macao... "Vaccination Temporarily Suspended"

Defect Found in Packaging Lid, Investigation Underway
Vaccination Temporarily Suspended Until Results Are Released

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Lee Hyun-woo] Health authorities in Hong Kong and Macau have announced a temporary suspension of vaccinations after discovering defects in the packaging caps of some Pfizer-BioNTech COVID-19 vaccines supplied through China's Fuxing Pharmaceuticals.

According to the South China Morning Post (SCMP) on the 24th, health authorities in Hong Kong and Macau stated that defects were found in the packaging caps of Pfizer-BioNTech vaccines with the batch number 210102, and vaccinations will be temporarily suspended while a safety investigation is underway.

The Pfizer-BioNTech vaccines supplied to Hong Kong and Macau were provided through China's Fuxing Pharmaceuticals, which has a supply contract with BioNTech. SCMP reported that BioNTech has also launched an investigation. Previously, last year, Fuxing Pharmaceuticals signed a supply contract with BioNTech, securing distribution rights for mainland China, Hong Kong, Macau, and Taiwan. In Hong Kong, the vaccine is reportedly referred to as the Fuxing-BioNTech vaccine.

Professor Ho Pak-leung, a microbiologist at the University of Hong Kong, explained in an interview with SCMP, "So far, there is no evidence suggesting any safety risks related to the packaging of this vaccine."

This content was produced with the assistance of AI translation services.